Copyright
©2014 Baishideng Publishing Group Inc.
World J Stem Cells. Sep 26, 2014; 6(4): 404-420
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.404
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.404
Table 2 Ongoing clinical trials of embryonic stem cell-derived cell transplantation
Clinical Trials.gov | Start (yr) | Sponsor | Status | Title | Condition | Intervention | Remarks |
NCT01344993 | 2011 | Advanced cell technology | Recruiting | Safety and tolerability of transplantation of MA09-hRPE cells in patients with advanced dry age related macular degeneration | Advanced dry age related macular degeneration | Sub-retinal transplantation of MA09-hRPE | A Phase I/II, open-label, multi-center, prospective study in United States. MA09-hRPE cells are human embryonic stem cell derived retinal Pigmented epithelial cells. |
NCT01345006 | 2011 | Advanced cell technology | Recruiting | Transplantation of MA09-hRPE cells in patients with stargardt's macular dystrophy | Stargardt's macular dystrophy | Sub-retinal transplantation of MA09-hRPE | A Phase I/II, open-label, multi-center, prospective study in United States |
NCT01469832 | 2011 | Advanced cell technology | Recruiting | Safety and tolerability of transplantation of hESC-RPE cells in patients with stargardt's macular dystrophy | Stargardt's macular dystrophy; fundus flavimaculatus; juvenile macular dystrophy | Sub-retinal transplantation of MA09-hRPE | A PhaseI/II, open-label, multi-center, prospective study in the United States |
NCT01625559 | 2012 | CHA Bio and diostech | Recruiting | Safety and tolerability of MA09-hRPE cells in patients with stargardt's macular dystrophy | Stargardt's macular dystrophy | Sub-retinal transplantation of MA09-hRPE | A Phase I, open-label, prospective study in Korea |
NCT01674829 | 2012 | CHA Bio and diostech | Recruiting | Safety and tolerability of transplantation of MA09-hRPE cells in patients with advanced dry age-related macular degeneration (AMD) | Dry age Related macular degeneration | Sub-retinal transplantation of MA09-hRPE | A Phase I/IIa, open-label, single-center, prospective study in Korea |
NCT01691261 | 2014 | Pfizer | Not yet recruiting | Implantation of human embryonic stem cell derived retinal pigment epithelium in subjects with acute wet age related macular degeneration and recent rapid vision decline | Age related macular degeneration | Implantation of human embryonic stem cell derived retinal pigment epithelium | Phase 1, open-label, safety and feasibility study in United Kingdom. PF-05206388 is human embryonic stem cell derived retinal pigment epithelium living tissue equivalent. |
NCT02057900 | 2013 | Assistance publique - hôpitaux de Paris | Recruiting | Transplantation of human embryonic stem cell-derived progenitors in severe heart failure (ESCORT) | Ischemic heart disease | Human embryonic stem cell-derived CD15+ Isl-1+ progenitors | Phase 1, open-label, feasibility and safety study in France |
NCT02122159 | 2014 | University of California, Los Angeles | Not yet recruiting | Research with retinal cells derived from embryonic stem cells for myopic macular degeneration | Myopic macular degeneration | MA09-hRPE cellular therapy | A Phase I/II, Open-label, prospective study to determine the safety and tolerability in United States |
- Citation: Ishii T, Eto K. Fetal stem cell transplantation: Past, present, and future. World J Stem Cells 2014; 6(4): 404-420
- URL: https://www.wjgnet.com/1948-0210/full/v6/i4/404.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v6.i4.404